Abel Hall, LLC Akebia Therapeutics, Inc. Transaction History
Abel Hall, LLC
- $216 Billion
- Q2 2025
A detailed history of Abel Hall, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Abel Hall, LLC holds 10,618 shares of AKBA stock, worth $31,216. This represents 0.02% of its overall portfolio holdings.
Number of Shares
10,618Holding current value
$31,216% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
170Shares Held
106MCall Options Held
134KPut Options Held
262K-
Vanguard Group Inc Valley Forge, PA14.6MShares$43 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$34.2 Million0.0% of portfolio
-
State Street Corp Boston, MA8MShares$23.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.07MShares$17.9 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$16.9 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $541M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...